CereCura is a preclincal biotherapeutics company harnessing lipid nanoparticle (LNP) and messenger RNA (mRNA) technologies to create novel genetic medicines for the treatment of intractable neurological disorders. The company leverages its proprietary brain ‘Bioreactor’ platform to allow a patient’s own cells to produce therapeutic proteins within the CNS, thereby circumventing the blood-brain barrier and directly delivering effective treatments for indications with high unmet medical needs.